跳到正文
原文
Medical Xpress·· 14 天前精选AI 评分65

科学家发现的药物加入世界最大帕金森病治疗试验

Drug discovery by scientists joins world's largest trial of Parkinson's treatments

AI 导读

一种用于治疗肝病的药物乌苯美司(UDCA)被纳入世界最大规模的帕金森病治疗试验。该药物通过保护多巴胺神经细胞,有望减缓帕金森病的进展。试验将招募2000名患者,评估UDCA与其他两种药物和安慰剂的效果。

推荐理由

该研究将一种已有30年历史的药物纳入大型临床试验,旨在评估其对帕金森病的疗效。

正文 · 原文
clinical trial
Credit: Unsplash/CC0 Public Domain

A liver drug could be used to slow down the progression of Parkinson's disease as it joins the world's largest trial of treatments for the condition.

This comes after researchers at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust discovered that ursodeoxycholic acid (UDCA) has considerable promise to improve the function of mitochondria, known as the cell's power plants, in Parkinson's disease and, by doing so, slow the progression of this currently relentlessly progressive disease.

UDCA was identified as a potential new avenue for treatment of Parkinson's following groundbreaking University of Sheffield–led research that screened an entire drug library in tissue samples from Parkinson's patients for the first time.

It is now the third of a new wave of treatments with disease-modifying potential to be tested in parallel against a placebo in the Edmond J Safra Accelerating Clinical Trials in Parkinson's Disease (EJS ACT-PD) trial.

The loss of mitochondrial function in dopamine-producing nerve cells in the movement-controlling area of the brain is believed to play an important role in the progression of Parkinson's. By protecting these nerve cells from cellular malfunction, researchers believe UDCA can play a key role in slowing Parkinson's progression.

The inclusion of the UDCA drug in the innovative multidrug EJS ACT-PD trial marks an important milestone for the platform, which aims to speed up the search for effective treatments for Parkinson's by testing more drugs faster and more efficiently than ever before. Up until now, there have been two active treatment arms (telmisartan and terazosin), with UDCA joining as the third active treatment arm.

UDCA has been used to treat certain liver conditions for over 30 years and was shown to be safe and well tolerated in people with Parkinson's disease in an early-stage clinical trial, the UP study. It was also strongly supported by the NIHR Biomedical Research Centre Sheffield.

However, large-scale testing is now needed to assess effectiveness further.

The drug was selected for inclusion in the EJS ACT-PD trial following an extensive review of hundreds of potential therapies by scientific experts and people with Parkinson's, identifying those with the strongest evidence for slowing Parkinson's disease progression.

As the UDCA treatment has a different dosing regimen from the two active treatments already being tested (telmisartan and terazosin), participants who join the trial from now on will be randomly assigned to one of five treatment groups (the three active treatments—UDCA, telmisartan and terazosin—and two placebo groups) depending on which they are eligible for.

The trial, which is being led nationally by researchers at University College London (UCL) and Newcastle University and managed by the UCL Innovative Clinical Trials Unit (InCTU), will recruit 2,000 participants from across 40 NHS hospital sites. Neither participants nor the study team know which treatments or placebo have been assigned while the trial is taking place.

The addition of UDCA to the EJS ACT-PD trial is also a particularly significant achievement for the Sheffield team as it is rare for an academically led drug discovery program to progress from initial laboratory discovery through a phase 2 trial with a novel design to a definitive phase 3 trial.

Oliver Bandmann, professor of movement disorders neurology at the University of Sheffield and honorary consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, led the drug's development and will act as co-lead of the UDCA treatment arm in the EJS ACT-PD trial together with professor Tom Foltynie at UCL and professor Camille Carroll at Newcastle University.

Bandmann said, "The launch of the UDCA arm of EJS ACT-PD represents a major milestone in a program of translational Parkinson's research jointly led by the University of Sheffield and Sheffield Teaching Hospitals and the NIHR Biomedical Research Centre (BRC) Sheffield over more than a decade.

"Our research began with the first systematic screening of an entire library of compounds in tissue from people with Parkinson's disease at the Sheffield Institute for Translational Neuroscience (SITraN). This identified UDCA, an existing medication for liver disease, as a promising candidate for protecting nerve cells by improving mitochondrial function.

"We subsequently took UDCA from the laboratory into a proof-of-concept clinical trial, the UP study, which demonstrated that the drug was safe and well tolerated in people with Parkinson's disease and provided encouraging evidence of its effects on brain energy metabolism."

He added, "Having led both the original drug discovery program and the UP study (together with professor Foltynie from UCL), I am particularly excited to now co-lead the definitive phase 3 evaluation of UDCA within EJS ACT-PD together with colleagues from UCL and Newcastle University.

"This is an excellent example of how discoveries made in patient-derived tissue can progress through early clinical testing toward large-scale trials, with the ultimate aim of developing treatments that slow or stop the progression of Parkinson's disease."

Carroll, professor of clinical neuroscience at Newcastle University and NIHR Newcastle BRC, said, "Bringing UDCA into the trial as a third treatment arm is exactly what our flexible design was built for: we can add promising drugs as the evidence for them emerges, within the same trial infrastructure, and so test more treatments more quickly. It is a great credit to the Sheffield team that a drug first identified in tissue from people with Parkinson's has now reached a large-scale trial."

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Drug discovery by scientists joins world's largest trial of Parkinson's treatments (2026, November 6) retrieved 6 November 2026 from https://medicalxpress.com/news/2026-11-drug-discovery-scientists-world-largest.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com